1. Clinical and economic benefits of de-escalating stress ulcer prophylaxis therapy in the intensive care unit: A quality improvement study
- Author
-
Richard Norman, Matthew Anstey, Andrew Chapman, Sneha Neppalli, Benedict J Tan, Ravikiran Sonawane, Edward Litton, Angela Jacques, Robert N Palmer, Ravi B Krishnamurthy, and David J Hawkins
- Subjects
Adult ,Peptic Ulcer ,medicine.medical_specialty ,Quality management ,Pharmacists ,Critical Care and Intensive Care Medicine ,law.invention ,03 medical and health sciences ,0302 clinical medicine ,Patient Education as Topic ,Stress, Physiological ,law ,Humans ,Medicine ,Prospective Studies ,030212 general & internal medicine ,Intensive care medicine ,Aged ,business.industry ,Stress ulcer ,Australia ,Proton Pump Inhibitors ,030208 emergency & critical care medicine ,Middle Aged ,Anti-Ulcer Agents ,medicine.disease ,Quality Improvement ,Economic benefits ,Intensive care unit ,Intensive Care Units ,Anesthesiology and Pain Medicine ,Potential harm ,Pharmacist prescribing ,Acute Disease ,business ,Stress, Psychological - Abstract
Stress ulcer prophylaxis is commonly prescribed in the intensive care unit but can be inappropriately commenced or continued on discharge, exposing patients to potential harm. We aimed to evaluate whether a prescribing guideline, education program and pharmacist oversight would reduce inappropriate continuation of stress ulcer prophylaxis. This was a multicentre pre- (2014) and post- (2016) quality improvement study across five Australian intensive care units. Cost data were estimated using local information about prescribing patterns, and the relationship between long-term use and adverse events. A total of 531 patients were included in the pre- and 393 in the post-implementation periods. The proportion of hospital survivors inappropriately continued on stress ulcer prophylaxis reduced from 78/184 (42.4%) to 11/143 (7.7%) in the post-implementation period (odds ratio = 8.83; 95% confidence interval 4.47–17.45; P
- Published
- 2019